drugset
drugset / Trial / NCT04266756

A Study of Selexipag in Healthy Male Participant

NCT04266756 ↗

Phase 1 Completed 24 enrolled Actelion
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetic (PK) of selexipag and ACT-333679 following single oral administration of the matrix tablet and the encapsulated pellets of selexipag, each with 3 different release profiles, as compared to selexipag immediate release (IR) tablets in healthy male participants.

Timeline

Start
2020-01-23
Primary completion
2020-08-14
Completion
2020-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Selexipag Small molecule — Oral

Indications

No indication recorded.